Bioretec publishes a company description for the contemplated listing of its shares on Nasdaq First North Growth Market Finland

Bioretec Ltd ("Bioretec" or the "Company") announced on 20 September 2021 that it had submitted a listing application with Nasdaq Helsinki Ltd ("Nasdaq Helsinki") for listing of the Company's shares (the "Shares") on Nasdaq First North Growth Market Finland maintained by Nasdaq Helsinki (the "Listing").

For the purposes of the Listing, Bioretec has prepared a Finnish-language company description in accordance with the Nasdaq First North Growth Market Rulebook (the "Company Description"). Nasdaq Helsinki has today, on 24 September 2021, reviewed the Company Description. The Company Description will be published on the website of the Company at www.bioretec.com/listautuminen on or about 24 September 2021.

Subject to the listing application of the Company being approved, trading in the Shares of the Company on Nasdaq First North Growth Market Finland is expected to commence on or about 28 September 2021. Nordic Certified Adviser AB will act as Bioretec's certified adviser in accordance with the Nasdaq First North Growth Market Rulebook.

Timo Lehtonen, CEO, tel. +358 50 433 8493

Tomi Numminen, Chairman of the Board, tel. +358 40 581 2132

Certified Adviser:

Nordic Certified Adviser AB, tel. +46 70 551 67 29

Bioretec’s mission is to promote healing after trauma or orthopedic surgery, building on a unique understanding of bioresorbable medical implants that act as scaffolds for tissue growth and eliminate the need for removal surgery of the implants. Bioretec's bioresorbable polymer implants are used worldwide and the Company intends to launch a new series of innovative implants based on a unique bioresorbable metallic alloy, RemeOs^TM. The RemeOs^TM product line is designed to meet the unmet medical need of demanding load-bearing fixations, and to facilitate a seamless transition for surgeons from conventional titanium implants. Better healing – Better life.